Analysts who follow Inovio Pharmaceuticals Inc (INO) on average expect it to climb 43.82% over the next twelve months. Those same analysts give the stock an average rating of Buy.
That average rating earns the stock an Analyst Ranking of 14, which means it ranks higher than 14 of stocks, based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Inovio Pharmaceuticals Inc Stock Today?
Inovio Pharmaceuticals Inc (INO) stock is up 5.07% while the S&P 500 has fallen -1.01% as of 10:29 AM on Friday, Jan 15. INO is up $0.48 from the previous closing price of $9.37 on volume of 3,511,691 shares. Over the past year the S&P 500 has risen 13.28% while INO is up 189.71%. INO lost -$1.35 per share the over the last 12 months.